Cadila Healthcare has reported results for first quarter ended June 30, 2017.
The company has reported a fall of 29.91% in its net profit after tax, Non-Controlling Interests and Share of Profits of joint ventures at Rs 91.40 crore for the quarter under review as compared to Rs 130.40 crore for the same quarter in the previous year. However, total income of the company increased by 13.44% at Rs 1107.40 crore for Q1FY18 as compared Rs 976.20 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported a fall of 65.26% in its net profit after tax, Non-Controlling Interests and Share of Profits of joint ventures at Rs 138.40 crore for the quarter under review as compared to Rs 398.40 crore for the same quarter in the previous year. Total income of the company decreased by 4.20% at Rs 2249.80 crore for Q1FY18 as compared Rs 2348.40 crore for the corresponding quarter previous year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: